Skin Cancer

EA6134 / DREAMseq



Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients with Stage III-IV BRAFV600 Melanoma

STATUS: Closed to Accrual


This phase III trial studies how well initial treatment with ipilimumab and nivolumab followed by dabrafenib and trametinib works and compares it to initial treatment with dabrafenib and trametinib followed by ipilimumab and nivolumab in treating patients with stage III-IV melanoma that contains a mutation known as BRAFV600 and cannot be removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Dabrafenib and trametinib may block tumor growth by targeting the BRAFV600 gene. It is not yet known whether treating patients with ipilimumab and nivolumab followed by dabrafenib and trametinib is more effective than treatment with dabrafenib and trametinib followed by ipilimumab and nivolumab.
  • STEP 1

  • Age >= 18 years. Because no dosing or adverse event data are currently available on the use of dabrafenib or dabrafenib + trametinib or nivolumab or nivolumab + ipilimumab therapy in patients < 18 years of age, children are excluded from this study, but will be eligible for future pediatric trials.

  • Eastern Cooperative Oncology Group (ECOG) performance status: 0 or 1

  • Women must not be pregnant or breast-feeding, as the effects of ipilimumab + nivolumab or dabrafenib + trametinib on the developing human fetus are unknown * All females of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy * A female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)

  • The effects of dabrafenib and trametinib or ipilimumab and nivolumab on the developing human fetus are unknown; furthermore, dabrafenib has been reported to interfere with the effect of hormone based oral contraceptives; for this reason and because other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and sexually active males must agree to use at least two other accepted and effective methods of contraception and/or to abstain from sexual intercourse for the duration of their participation in the study, and for at least 4 weeks after treatment with dabrafenib or for 4 months after dabrafenib in combination with trametinib; women of child-bearing potential must use at least two other accepted and effective methods of contraception and/or to abstain from sexual intercourse for at least 5 months after the last dose of nivolumab and/or ipilimumab and sexually active males must use at least two other accepted and effective methods of contraception and/or abstain from sexual intercourse for at least 7 months after the last dose of nivolumab and/or ipilimumab; should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately

  • Patients must have unresectable stage III or stage IV disease

  • Patients must have measurable disease; all sites of disease must be evaluated within 4 weeks prior to randomization

  • Patients must have histological or cytological confirmation of melanoma that is metastatic or unresectable and clearly progressive * NOTE: Any patient with BRAF V600 mutant melanoma (whether cutaneous, acral or mucosal primary) who meets the eligibility criteria is eligible for participation in this trial; patients with uveal melanoma are not eligible for this trial

  • Patients must have BRAF V600 mutation, identified by a Food and Drug Administration (FDA)-approved test at a Clinical Laboratory Improvement Act (CLIA)-certified lab; if test at CLIA-certified lab used a non-FDA approved method, information about the assay must be provided (FDA approved tests for BRAF V600 mutations in melanoma include: THxID BRAF Detection Kit and Cobas 4800 BRAF V600 Mutation Test, Foundation Medicine); prompt information on tumor BRAF mutation status can also be obtained via Novartis “knowNow” Program

  • Patients may have had prior systemic therapy in the adjuvant setting; however this adjuvant treatment must not have included a CTLA4 or PD1 pathway blocking antibody or a BRAF/MEK inhibitor. Also, patients may not have had any prior systemic treatment for advanced (measurable metastatic) disease

  • Patients must have discontinued chemotherapy, immunotherapy or other investigational agents used in the adjuvant setting >= 4 weeks prior to entering the study and recovered from adverse events due to those agents; mitomycin and nitrosoureas must have been discontinued at least 6 weeks prior to entering the study; patients must have discontinued radiation therapy >= 1 week prior to entering the study and recovered from any adverse events associated with treatment; prior surgery must be >= 2 weeks from registration and patients must be fully recovered from post-surgical complications

  • Patients must not receive any other investigational agents while on study or within four weeks prior to registration

  • Patients are ineligible if they have any currently active central nervous system (CNS) metastases; patients who have treated brain metastases (with either surgical resection or stereotactic radiosurgery [SRS]) could be eligible; patients must not have taken any steroids =< 10 days prior to randomization for the purpose of managing their brain metastases; repeat imaging after SRS or surgical resection is not required so long as baseline magnetic resonance imaging (MRI) is within 4 weeks of registration; patients with multiple brain metastases treated with SRS (with [w] or without [w/o] whole-brain radiotherapy [WBRT]), are not an exclusion; patients with definitive CNS metastases treated with only WBRT are ineligible; patients with potential CNS metastases that are too small for treatment with either SRS or surgery (e.g. 1-2 mm) and/or are of uncertain etiology are potentially eligible, but need to be discussed with and approved by the study principal investigator (PI)

  • Patients must not have other current malignancies, other than basal cell skin cancer, squamous cell skin cancer, in situ cervical cancer, ductal or lobular carcinoma in situ of the breast; patients with other malignancies are eligible if they have been continuously disease-free for > 2 years prior to the time of registration

  • White blood count >= 3,000/uL (obtained within 4 weeks prior to randomization)

  • Absolute neutrophil count (ANC) >= 1,500/uL (obtained within 4 weeks prior to randomization)

  • Platelet count >= 100,000/uL (obtained within 4 weeks prior to randomization)

  • Hemoglobin > 8 g/dL (obtained within 4 weeks prior to randomization)

  • Serum creatinine =< 1.5 x upper limit of normal (ULN) or serum creatinine clearance (CrCl) >= 40 ml/min (obtained within 4 weeks prior to randomization)

  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN (=< 5 x ULN for patients with documented liver metastases)

  • Alkaline phosphatase =< 2 x ULN (=< 5 x ULN for patients with known liver involvement and =< 7 x ULN for patients with known bone involvement) (obtained within 4 weeks prior to randomization)

  • Total bilirubin =< 1.5 x ULN except subjects with normal direct bilirubin or those with known Gilbert’s syndrome (obtained within 4 weeks prior to randomization)

  • Patients must not have any serious or unstable pre-existing medical conditions (aside from malignancy exceptions specified above), including but not limited to, ongoing or active infection requiring parenteral antibiotics on day 1, or psychiatric illness/social situations that would limit compliance with study requirements, interfere with subject’s safety, or obtaining informed consent; therapeutic level dosing of warfarin can be used with close monitoring of prothrombin time (PT)/international normalized ratio (INR) by the site; exposure may be decreased due to enzyme induction when on treatment, thus warfarin dosing may need to be adjusted based upon PT/INR; consequently, when discontinuing dabrafenib, warfarin exposure may be increased and thus close monitoring via PT/INR and warfarin dose adjustments must be made as clinically appropriate; prophylactic low dose warfarin may be given to maintain central catheter patency

  • Patients must not have a history of or evidence of cardiovascular risks including any of the following: * QT interval corrected for heart rate using the Bazett’s formula (QTcB) >= 480 msec. at baseline * History of acute coronary syndromes (including myocardial infarction or unstable angina), coronary angioplasty, or stenting within the past 24 weeks prior to registration * History prior to registration or evidence of current >= class II congestive heart failure as defined by the New York Heart Association (NYHA) functional classification system * Left ventricular ejection fraction (LVEF) =< 45% on cardiac echocardiogram (echo) or multi gated acquisition scan (MUGA) * Intra-cardiac defibrillator

  • Individuals who are known to be human immunodeficiency virus (HIV) infected are ineligible (note: HIV testing is not required for entry into the study)

  • Patients with active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids, should be excluded; these include but are not limited to patients with a history of immune related neurologic disease, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis; systemic autoimmune disease such as systemic lupus erythematosus (SLE), connective tissue diseases, scleroderma, inflammatory bowel disease (IBD), Crohn’s, ulcerative colitis, hepatitis; and patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome should be excluded because of the risk of recurrence or exacerbation of disease; patients with vitiligo, endocrine deficiencies including thyroiditis managed with replacement hormones including physiologic corticosteroids are eligible; patients with rheumatoid arthritis and other arthropathies, Sjogren’s syndrome and psoriasis controlled with topical medication and patients with positive serology, such as antinuclear antibodies (ANA), should be evaluated for the presence of target organ involvement and potential need for systemic treatment; if no systemic immune suppression is deemed necessary they can be eligible

  • The following medications or non-drug therapies are also prohibited while on treatment in this study: * Other anti-cancer therapies * Other investigational drugs * Patients taking any medications or substances that are strong inhibitors or inducers of CYP3A or CYP2C8 are ineligible

  • Patients must not have history of retinal vein occlusion (RVO)

  • Patients must not have evidence of interstitial lung disease or pneumonitis

  • Patients must not have malabsorption, swallowing difficulty, or other conditions that would interfere with the ingestion or absorption of dabrafenib or trametinib

  • STEP 2 (CROSSOVER ARMS): The patient must have met all eligibility criteria (except as detailed below) at the time of crossover * RECIST defined measurable disease is not required * Only prior systemic therapy as part of step 1 is allowed; patients who received allowed systemic therapy in the adjuvant setting prior to Step 1 and were eligible for Step 1 are not excluded from proceeding to Step 2 if they meet other eligibility criteria * Malabsorption, swallowing difficulty, or other conditions that would interfere with the ingestion or absorption of dabrafenib or trametinib, or history of retinal vein occlusion are acceptable for patients crossing over to Arm D (ipilimumab + nivolumab) treatment * History of autoimmune disease, excluding interstitial lung disease or pneumonitis, is allowed in patients crossing over to Arm C (dabrafenib/trametinib) therapy * Patients crossing over from Arm A (nivolumab/ipilimumab) to Arm C (dabrafenib/trametinib) who underwent surgery or SRS to CNS metastases need not be off of steroids to start treatment * There is no restriction on serum lactate dehydrogenase (LDH) at crossover * Patients with a history of cardiovascular risks that developed during step 1 of therapy should be discussed with study principal investigator (PI) at time of crossover

  • STEP 2 (CROSSOVER ARMS): Patients randomized to Arm A on Step 1 must have melanoma that is metastatic and clearly progressive on Step 1 therapy prior to crossing over to Arm C * NOTE: Patients should (if possible) be at least 1 week from documented PD on Step 1 of current study. All sites of disease must be evaluated within 4 weeks prior to registration

  • STEP 2 (CROSSOVER ARMS): Patients randomized to Arm B on Step 1 may cross over to Arm D at or prior to disease progression * NOTE: If possible, patients should wait to cross over until after the cycle with the next protocol-required imaging assessment is completed; all sites of disease must be evaluated within 4 weeks prior to Step 2 registration * NOTE: Patients should start Arm D treatment at least 1 week after stopping dabrafenib and trametinib, unless otherwise clinically indicated * NOTE: Baseline labs and QOL assessments should be completed, and patients should follow the Arm D schedule

  • STEP 2 (CROSSOVER ARMS): Patients must have recovered from adverse events (toxicities resolved to grade 1 or less) of prior therapy; patients with immune related toxicities from ipilimumab + nivolumab may continue onto Step 2 even if still on steroids to control side effects, so long as toxicity has resolved to grade 1 or less

  • STEP 2 (CROSSOVER ARMS): Patients must have discontinued radiation therapy prior to registering to Step 2 of the study and recovered from any adverse events associated with treatment; prior surgery must be >= 2 weeks from registration to Step 2 and patients must be fully recovered from post-surgical complications

  • STEP 2 (CROSSOVER ARMS): Patients are ineligible if they have any currently active and definitive CNS metastases; patients who have treated brain metastases (with either surgical resection or stereotactic radiosurgery [SRS]) could be eligible to proceed; patients crossing over from Arm B (dabrafenib/trametinib) to Arm D (nivolumab [nivo]/ipilimumab [ipi]) must not have taken any steroids =< 10 days prior to Step 2 registration for the purpose of managing their brain metastases; patients with only whole brain irradiation for treatment of CNS metastases are ineligible; patients with definitive CNS metastases treated with only WBRT are ineligible; patients with potential CNS metastases that are too small for treatment with either SRS or surgery (e.g. 1-2 mm) and/or are of uncertain etiology are potentially eligible, but need to be discussed with and approved by the study PI

  • STEP 2 (CROSSOVER ARMS): Patients must not have other current malignancies

  • STEP 2 (CROSSOVER ARMS): Women must not be pregnant or breast-feeding, as the effects of ipilimumab + nivolumab or dabrafenib + trametinib on the developing human fetus are unknown; all females of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to Step 2 crossover to rule out pregnancy; a female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months

  • STEP 2 (CROSSOVER ARMS): The effects of dabrafenib and trametinib or ipilimumab and nivolumab on the developing human fetus are unknown; furthermore, dabrafenib has been reported to interfere with the effect of hormone based oral contraceptives; for this reason and because other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and sexually active males must agree to continue to use the same contraception requirements as on Step 1 of this study (i.e.: use at least two other accepted and effective methods of contraception and/or to abstain from sexual intercourse for the duration of their participation in the study, and for at least 4 weeks after treatment with dabrafenib or for 4 months after dabrafenib in combination with trametinib; women of child-bearing potential must use at least two other accepted and effective methods of contraception and/or to abstain from sexual intercourse for at least 5 months after the last dose of nivolumab and/or ipilimumab and sexually active males must use at least two other accepted and effective methods of contraception and/or to abstain from sexual intercourse for at least 7 months after the last dose of nivolumab and/or ipilimumab); should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately

United States
AK
Anchorage
Alaska Breast Care and Surgery LLC
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: AKPAMC.OncologyResearchSupport@providence.org

Alaska Oncology and Hematology LLC
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: AKPAMC.OncologyResearchSupport@providence.org

Alaska Women's Cancer Care
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: AKPAMC.OncologyResearchSupport@providence.org

Anchorage Associates in Radiation Medicine
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: AKPAMC.OncologyResearchSupport@providence.org

Anchorage Oncology Centre
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: AKPAMC.OncologyResearchSupport@providence.org

Anchorage Radiation Therapy Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: AKPAMC.OncologyResearchSupport@providence.org

Katmai Oncology Group
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: AKPAMC.OncologyResearchSupport@providence.org

Providence Alaska Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: AKPAMC.OncologyResearchSupport@providence.org

Fairbanks
Fairbanks Memorial Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Veronica.Stevenson@foundationhealth.org

AL
Birmingham
University of Alabama at Birmingham Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: tmyrick@uab.edu

AR
Hot Springs
CHI Saint Vincent Cancer Center Hot Springs
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinicaltrials@sfmc-gi.org

Little Rock
University of Arkansas for Medical Sciences
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

AZ
Goodyear
CTCA at Western Regional Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Kingman
Kingman Regional Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@sncrf.org

Phoenix
Cancer Center at Saint Joseph's
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

CA
Anaheim
Kaiser Permanente-Anaheim
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinical.trials@kp.org

Arroyo Grande
Mission Hope Medical Oncology - Arroyo Grande
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@dignityhealth.org

PCR Oncology
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@sncrf.org

Auburn
Sutter Auburn Faith Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: bernicl@sutterhealth.org

Sutter Cancer Centers Radiation Oncology Services-Auburn
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: bernicl@sutterhealth.org

Baldwin Park
Kaiser Permanente-Baldwin Park
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinical.trials@kp.org

Bellflower
Kaiser Permanente-Bellflower
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinical.trials@kp.org

Berkeley
Alta Bates Summit Medical Center-Herrick Campus
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: bernicl@sutterhealth.org

Burbank
Providence Saint Joseph Medical Center / Disney Family Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Najee.Boucher@providence.org

Burlingame
Mills-Peninsula Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: bernicl@sutterhealth.org

Cameron Park
Sutter Cancer Centers Radiation Oncology Services-Cameron Park
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: bernicl@sutterhealth.org

Castro Valley
Eden Hospital Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: bernicl@sutterhealth.org

Chico
Adventist Health Cancer Care Center Chico
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: hs-ccnctrials@ucdavis.edu

Davis
Sutter Davis Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: bernicl@sutterhealth.org

Duarte
City of Hope Comprehensive Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: becomingapatient@coh.org

Dublin
Kaiser Permanente Dublin
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Fontana
Kaiser Permanente-Fontana
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinical.trials@kp.org

Fremont
Palo Alto Medical Foundation-Fremont
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: bernicl@sutterhealth.org

Fresno
Kaiser Permanente-Fresno
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Kpoct@kp.org

Harbor City
Kaiser Permanente - Harbor City
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinical.trials@kp.org

Irvine
Kaiser Permanente-Irvine
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinical.trials@kp.org

Los Angeles
Kaiser Permanente Los Angeles Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinical.trials@kp.org

Kaiser Permanente West Los Angeles
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinical.trials@kp.org

UCLA / Jonsson Comprehensive Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Modesto
Kaiser Permanente-Modesto
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Kpoct@kp.org

Memorial Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: bernicl@sutterhealth.org

Mountain View
Palo Alto Medical Foundation-Camino Division
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: bernicl@sutterhealth.org

Palo Alto Medical Foundation-Gynecologic Oncology
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: bernicl@sutterhealth.org

Novato
Sutter Cancer Research Consortium
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: bernicl@sutterhealth.org

Oakland
Kaiser Permanente-Oakland
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Kpoct@kp.org

Ontario
Kaiser Permanente-Ontario
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinical.trials@kp.org

Palo Alto
Palo Alto Medical Foundation Health Care
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: bernicl@sutterhealth.org

Panorama City
Kaiser Permanente - Panorama City
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinical.trials@kp.org

Rancho Mirage
Eisenhower Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Richmond
Kaiser Permanente-Richmond
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Kpoct@kp.org

Riverside
Kaiser Permanente-Riverside
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinical.trials@kp.org

Roseville
Kaiser Permanente-Roseville
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Kpoct@kp.org

Sutter Cancer Centers Radiation Oncology Services-Roseville
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: bernicl@sutterhealth.org

Sutter Roseville Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: bernicl@sutterhealth.org

Sacramento
Kaiser Permanente - Sacramento
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Kpoct@kp.org

Kaiser Permanente Downtown Commons
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: kpoct@kp.org

Kaiser Permanente-South Sacramento
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Kpoct@kp.org

Sutter Medical Center Sacramento
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: bernicl@sutterhealth.org

San Diego
Kaiser Permanente-San Diego Mission
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinical.trials@kp.org

Kaiser Permanente-San Diego Zion
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinical.trials@kp.org

San Francisco
California Pacific Medical Center-Pacific Campus
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: bernicl@sutterhealth.org

San Jose
Kaiser Permanente-Santa Teresa-San Jose
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Kpoct@kp.org

San Leandro
Kaiser Permanente San Leandro
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Kpoct@kp.org

San Luis Obispo
Pacific Central Coast Health Center-San Luis Obispo
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Diane.DeVos-Schmidt@DignityHealth.org

San Marcos
Kaiser Permanente-San Marcos
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinical.trials@kp.org

San Mateo
Mills Health Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: ctsucontact@westat.com

San Rafael
Kaiser Permanente-San Rafael
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Kpoct@kp.org

Kaiser San Rafael-Gallinas
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Kpoct@kp.org

Santa Clara
Kaiser Permanente Medical Center - Santa Clara
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Kpoct@kp.org

Santa Cruz
Palo Alto Medical Foundation-Santa Cruz
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: bernicl@sutterhealth.org

Santa Maria
Mission Hope Medical Oncology - Santa Maria
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@dignityhealth.org

Santa Rosa
Sutter Pacific Medical Foundation
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: bernicl@sutterhealth.org

Stockton
Kaiser Permanente-Stockton
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Kpoct@kp.org

Sunnyvale
Palo Alto Medical Foundation-Sunnyvale
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: bernicl@sutterhealth.org

Upland
City of Hope Upland
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: becomingapatient@coh.org

Vacaville
Kaiser Permanente Medical Center-Vacaville
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Kpoct@kp.org

Sutter Cancer Centers Radiation Oncology Services-Vacaville
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: bernicl@sutterhealth.org

Vallejo
Kaiser Permanente-Vallejo
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Kpoct@kp.org

Sutter Solano Medical Center / Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: bernicl@sutterhealth.org

Walnut Creek
Kaiser Permanente-Walnut Creek
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Kpoct@kp.org

Woodland Hills
Kaiser Permanente-Woodland Hills
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinical.trials@kp.org

CO
Aurora
The Medical Center of Aurora
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: info@westernstatesncorp.org

University of Colorado Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Boulder
Boulder Community Hospital
Status: TEMPORARILY_CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: jbloomfield@co-cancerresearch.org

Colorado Springs
Memorial Hospital North
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Penrose-Saint Francis Healthcare
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinicaltrials@sfmc-gi.org

Rocky Mountain Cancer Centers-Penrose
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: info@westernstatesncorp.org

Saint Francis Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

UCHealth Memorial Hospital Central
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Denver
Porter Adventist Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinicaltrials@sfmc-gi.org

Presbyterian - Saint Lukes Medical Center - Health One
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: info@westernstatesncorp.org

Rose Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: ccrp@co-cancerresearch.org

SCL Health Saint Joseph Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: alan.franklin@sclhealth.org

Durango
Mercy Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinicaltrials@sfmc-gi.org

Southwest Oncology PC
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinicaltrials@sfmc-gi.org

Englewood
Mountain Blue Cancer Care Center - Swedish
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: info@westernstatesncorp.org

Swedish Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: info@westernstatesncorp.org

Fort Collins
Poudre Valley Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Golden
Mountain Blue Cancer Care Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinicaltrials@sfmc-gi.org

Grand Junction
Grand Valley Oncology
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: gvoclinicaltrials@gjhosp.org

Greeley
North Colorado Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: info@westernstatesncorp.org

Lakewood
Rocky Mountain Cancer Centers-Lakewood
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: info@westernstatesncorp.org

Saint Anthony Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinicaltrials@sfmc-gi.org

Littleton
Littleton Adventist Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinicaltrials@sfmc-gi.org

Lone Tree
Sky Ridge Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: info@westernstatesncorp.org

Longmont
Longmont United Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinicaltrials@sfmc-gi.org

Rocky Mountain Cancer Centers-Longmont
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: info@westernstatesncorp.org

Loveland
McKee Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: info@westernstatesncorp.org

Parker
Parker Adventist Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinicaltrials@sfmc-gi.org

Rocky Mountain Cancer Centers-Parker
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: info@westernstatesncorp.org

Pueblo
Rocky Mountain Cancer Centers - Pueblo
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: info@westernstatesncorp.org

Saint Mary Corwin Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinicaltrials@sfmc-gi.org

Thornton
Rocky Mountain Cancer Centers-Thornton
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: info@westernstatesncorp.org

Wheat Ridge
SCL Health Lutheran Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: ccrp@co-cancerresearch.org

CT
Hartford
Smilow Cancer Hospital Care Center at Saint Francis
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: canceranswers@yale.edu

New Haven
Smilow Cancer Center / Yale-New Haven Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: canceranswers@yale.edu

Yale University
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: canceranswers@yale.edu

Norwich
Eastern Connecticut Hematology and Oncology Associates
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Stamford
Stamford Hospital / Bennett Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

DC
Washington
MedStar Georgetown University Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

MedStar Washington Hospital Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

DE
Newark
Christiana Care Health System-Christiana Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: mhayden@christianacare.org

Christiana Gynecologic Oncology LLC
Status: TEMPORARILY_CLOSED_TO_ACCRUAL
Contact: Gregory Andrew Masters

Delaware Clinical and Laboratory Physicians PA
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: mhayden@christianacare.org

Helen F Graham Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: mhayden@christianacare.org

Medical Oncology Hematology Consultants PA
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: mhayden@christianacare.org

Wilmington
Christiana Care Health System-Wilmington Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: mhayden@christianacare.org

FL
Aventura
Mount Sinai Comprehensive Cancer Center at Aventura
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: yenrique@msmc.com

Coral Gables
UM Sylvester Comprehensive Cancer Center at Coral Gables
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Daytona Beach
Halifax Health Medical Center-Centers for Oncology
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Deerfield Beach
UM Sylvester Comprehensive Cancer Center at Deerfield Beach
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Fort Lauderdale
Holy Cross Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Lakeland
Lakeland Regional Health Hollis Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Miami
UM Sylvester Comprehensive Cancer Center at Kendall
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

University of Miami Miller School of Medicine-Sylvester Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Miami Beach
Mount Sinai Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: yenrique@msmc.com

Orlando
Orlando Health Cancer Institute
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: CancerClinicalTrials@orlandohealth.com

Plantation
UM Sylvester Comprehensive Cancer Center at Plantation
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

GA
Athens
University Cancer and Blood Center LLC
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@universitycancer.com

Atlanta
Emory Saint Joseph's Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Emory University Hospital / Winship Cancer Institute
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Northside Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: ClinicalTrials@northside.com

Augusta
Augusta University Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: ga_cares@augusta.edu

Cumming
Northside Hospital-Forsyth
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinicaltrials@northside.com

Decatur
Dekalb Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinicaltrialsoncology@dekalbmedical.org

Duluth
Northside Hospital - Duluth
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Clinical.trials@northside.com

Lawrenceville
Northside Hospital - Gwinnett
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Clinical.trials@northside.com

Savannah
Lewis Cancer and Research Pavilion at Saint Joseph's / Candler
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: underberga@sjchs.org

Summit Cancer Care-Candler
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: ecog.rss@jimmy.harvard.edu

Snellville
Suburban Hematology Oncology Associates - Snellville
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Clinical.trials@northside.com

HI
Aiea
Hawaii Cancer Care - Savio
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: info@hawaiicancercare.com

Pali Momi Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Queen's Cancer Center - Pearlridge
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Straub Pearlridge Clinic
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

The Cancer Center of Hawaii-Pali Momi
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Ewa Beach
The Queen's Medical Center - West Oahu
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: rohta@queens.org

Honolulu
Hawaii Cancer Care Inc - Waterfront Plaza
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: i.webster@hawaiicancercare.com

Hawaii Cancer Care Inc-Liliha
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Hawaii Diagnostic Radiology Services LLC
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: mmiyoshi@hawaiidrs.com

Island Urology
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: virginia@cc.hawaii.edu

Kaiser Permanente Moanalua Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: shelley.a.clark@kp.org

Kapiolani Medical Center for Women and Children
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Kuakini Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Queen's Cancer Cenrer - POB I
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Queen's Cancer Center - Kuakini
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Queen's Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Straub Clinic and Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

The Cancer Center of Hawaii-Liliha
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

University of Hawaii Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Kahului
Straub Medical Center - Kahului Clinic
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: lori.kam@hawaiipacifichealth.org

Kailua
Castle Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: ctsucontact@westat.com

Lihue
Wilcox Memorial Hospital and Kauai Medical Clinic
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

IA
Ames
Mary Greeley Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

McFarland Clinic PC - Ames
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: ksoder@mcfarlandclinic.com

Boone
McFarland Clinic PC-Boone
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Clive
Medical Oncology and Hematology Associates-West Des Moines
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinicaltrials@sfmc-gi.org

Mercy Cancer Center-West Lakes
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinicaltrials@sfmc-gi.org

Council Bluffs
Alegent Health Mercy Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinicaltrials@sfmc-gi.org

Creston
Greater Regional Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinicaltrials@sfmc-gi.org

Des Moines
Mercy Medical Center - Des Moines
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinicaltrials@sfmc-gi.org

Mission Cancer and Blood - Laurel
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinicaltrials@sfmc-gi.org

Fort Dodge
McFarland Clinic PC-Trinity Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Jefferson
McFarland Clinic PC-Jefferson
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Marshalltown
McFarland Clinic PC-Marshalltown
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Sioux City
Siouxland Regional Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: HoopingarnerT@jencc.com

West Des Moines
Mercy Medical Center-West Lakes
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinicaltrials@sfmc-gi.org

ID
Boise
Saint Alphonsus Cancer Care Center-Boise
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: stephanie.couch@stjoeshealth.org

Saint Luke's Cancer Institute - Boise
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: eslinget@slhs.org

Caldwell
Saint Alphonsus Cancer Care Center-Caldwell
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: stephanie.couch@stjoeshealth.org

Coeur D'Alene
Kootenai Health - Coeur d'Alene
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: mccinfo@mtcancer.org

Emmett
Walter Knox Memorial Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: stephanie.couch@stjoeshealth.org

Fruitland
Saint Luke's Cancer Institute - Fruitland
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: eslinget@slhs.org

Meridian
Idaho Urologic Institute-Meridian
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: stephanie.couch@stjoeshealth.org

Saint Luke's Cancer Institute - Meridian
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: eslinget@slhs.org

Nampa
Saint Alphonsus Medical Center-Nampa
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: mccinfo@mtcancer.org

Saint Luke's Cancer Institute - Nampa
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: eslinget@slhs.org

Post Falls
Kootenai Clinic Cancer Services - Post Falls
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: mccinfo@mtcancer.org

Sandpoint
Kootenai Cancer Clinic
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: mccinfo@mtcancer.org

Twin Falls
Saint Luke's Cancer Institute - Twin Falls
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: eslinget@slhs.org

IL
Aurora
Rush - Copley Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Cancer.Research@rushcopley.com

Bloomington
Illinois CancerCare-Bloomington
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: andersonj@illinoiscancercare.com

Saint Joseph Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: andersonj@illinoiscancercare.com

Canton
Illinois CancerCare-Canton
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: andersonj@illinoiscancercare.com

Carbondale
Memorial Hospital of Carbondale
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinical.research@sih.net

Carterville
SIH Cancer Institute
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinical.research@sih.net

Carthage
Illinois CancerCare-Carthage
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: andersonj@illinoiscancercare.com

Centralia
Centralia Oncology Clinic
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: morganthaler.jodi@mhsil.com

Chicago
Northwestern University
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: cancer@northwestern.edu

Rush University Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinical_trials@rush.edu

Danville
Carle on Vermilion
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Research@carle.com

DeKalb
Northwestern Medicine Cancer Center Kishwaukee
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Donald.Smith3@nm.org

Decatur
Cancer Care Specialists of Illinois - Decatur
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: morganthaler.jodi@mhsil.com

Decatur Memorial Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: morganthaler.jodi@mhsil.com

Dixon
Illinois CancerCare-Dixon
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Effingham
Carle Physician Group-Effingham
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Research@carle.com

Crossroads Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: morganthaler.jodi@mhsil.com

Eureka
Illinois CancerCare-Eureka
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: andersonj@illinoiscancercare.com

Evanston
NorthShore University HealthSystem-Evanston Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Galesburg
Illinois CancerCare-Galesburg
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: andersonj@illinoiscancercare.com

Western Illinois Cancer Treatment Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Geneva
Northwestern Medicine Cancer Center Delnor
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Donald.Smith3@nm.org

Glenview
NorthShore University HealthSystem-Glenbrook Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Highland Park
NorthShore University HealthSystem-Highland Park Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Joliet
Duly Health and Care Joliet
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Karen.Sceniak@dulyhealthandcare.com

Kewanee
Illinois CancerCare-Kewanee Clinic
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: andersonj@illinoiscancercare.com

Lake Forest
Northwestern Medicine Lake Forest Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: cancertrials@northwestern.edu

Macomb
Illinois CancerCare-Macomb
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: andersonj@illinoiscancercare.com

Mattoon
Carle Physician Group-Mattoon / Charleston
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Research@carle.com

Maywood
Loyola University Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

O'Fallon
Cancer Care Center of O'Fallon
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: morganthaler.jodi@mhsil.com

Ottawa
Illinois CancerCare-Ottawa Clinic
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: andersonj@illinoiscancercare.com

Pekin
Illinois CancerCare-Pekin
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: andersonj@illinoiscancercare.com

OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: andersonj@illinoiscancercare.com

Peoria
Illinois CancerCare-Peoria
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: andersonj@illinoiscancercare.com

Methodist Medical Center of Illinois
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: andersonj@illinoiscancercare.com

OSF Saint Francis Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: andersonj@illinoiscancercare.com

OSF Saint Francis Radiation Oncology at Peoria Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: andersonj@illinoiscancercare.com

Peru
Illinois CancerCare-Peru
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: andersonj@illinoiscancercare.com

Valley Radiation Oncology
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Princeton
Illinois CancerCare-Princeton
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: andersonj@illinoiscancercare.com

Springfield
Memorial Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Southern Illinois University School of Medicine
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Springfield Clinic
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Swansea
Southwest Illinois Health Services LLP
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: lynns@thecancercenter.com

Urbana
Carle Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Research@carle.com

The Carle Foundation Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Research@carle.com

Warrenville
Northwestern Medicine Cancer Center Warrenville
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Donald.Smith3@nm.org

Washington
Illinois CancerCare - Washington
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: andersonj@illinoiscancercare.com

Yorkville
Rush-Copley Healthcare Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Cancer.Research@rushcopley.com

IN
Evansville
Deaconess Clinic Downtown
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Research@Deaconess.com

Indianapolis
Franciscan Health Indianapolis
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Indiana University / Melvin and Bren Simon Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: iutrials@iu.edu

Kendrick Colon and Rectal Center-Indianapolis
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Sidney and Lois Eskenazi Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: iutrials@iu.edu

Springmill Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: iutrials@iu.edu

Michigan City
Woodland Cancer Care Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: sally.arnett@franciscanalliance.org

Mooresville
Franciscan Health Mooresville
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Newburgh
Chancellor Center for Oncology
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Research@Deaconess.com

Richmond
Reid Health
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org

KS
Chanute
Cancer Center of Kansas - Chanute
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Keisha.humphries@ascension.org

Coffeyville
Coffeyville Regional Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Dodge City
Cancer Center of Kansas - Dodge City
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Keisha.humphries@ascension.org

El Dorado
Cancer Center of Kansas - El Dorado
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Keisha.humphries@ascension.org

Fort Scott
Cancer Center of Kansas - Fort Scott
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Keisha.humphries@ascension.org

Garden City
Central Care Cancer Center - Garden City
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: aroland@kccop.org

Saint Catherine Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: info@cccancer.com

Great Bend
Central Care Cancer Center - Great Bend
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: aroland@kccop.org

Saint Rose Ambulatory and Surgery Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Hays
HaysMed University of Kansas Health System
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Independence
Cancer Center of Kansas-Independence
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Keisha.humphries@ascension.org

Kansas City
University of Kansas Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: KUCC_Navigation@kumc.edu

University of Kansas Cancer Center-West
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: KUCC_Navigation@kumc.edu

Kingman
Cancer Center of Kansas-Kingman
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Keisha.humphries@ascension.org

Lawrence
Lawrence Memorial Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Stephanie.Norris@LMH.ORG

Liberal
Cancer Center of Kansas-Liberal
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Keisha.humphries@ascension.org

Manhattan
Cancer Center of Kansas-Manhattan
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Keisha.humphries@ascension.org

McPherson
Cancer Center of Kansas - McPherson
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Keisha.humphries@ascension.org

Newton
Cancer Center of Kansas - Newton
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Keisha.humphries@ascension.org

Olathe
Olathe Health Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Jeni.wakefield@olathehealth.org

Overland Park
Menorah Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: aroland@kccop.org

University of Kansas Cancer Center-Overland Park
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: KUCC_Navigation@kumc.edu

Parsons
Cancer Center of Kansas - Parsons
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Keisha.humphries@ascension.org

Pittsburg
Ascension Via Christi - Pittsburg
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: jennifer.jameson@ascension.org

Pratt
Cancer Center of Kansas - Pratt
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Keisha.humphries@ascension.org

Salina
Cancer Center of Kansas - Salina
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Keisha.humphries@ascension.org

Salina Regional Health Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: mleepers@srhc.com

Topeka
University of Kansas Health System Saint Francis Campus
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Wellington
Cancer Center of Kansas - Wellington
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Keisha.humphries@ascension.org

Westwood
University of Kansas Hospital-Westwood Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: KUCC_Navigation@kumc.edu

Wichita
Ascension Via Christi Hospitals Wichita
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Keisha.humphries@ascension.org

Associates In Womens Health
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Keisha.humphries@ascension.org

Cancer Center of Kansas - Wichita
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Keisha.humphries@ascension.org

Cancer Center of Kansas-Wichita Medical Arts Tower
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Keisha.humphries@ascension.org

Winfield
Cancer Center of Kansas - Winfield
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Keisha.humphries@ascension.org

KY
Bardstown
Flaget Memorial Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinicaltrials@sfmc-gi.org

Corbin
Commonwealth Cancer Center-Corbin
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinicaltrials@sfmc-gi.org

Crestview Hills
Oncology Hematology Care Inc-Crestview
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org

Lexington
Saint Joseph Hospital East
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinicaltrials@sfmc-gi.org

Saint Joseph Radiation Oncology Resource Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinicaltrials@sfmc-gi.org

London
Saint Joseph London
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinicaltrials@sfmc-gi.org

Louisville
Jewish Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinicaltrials@sfmc-gi.org

Saints Mary and Elizabeth Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinicaltrials@sfmc-gi.org

The James Graham Brown Cancer Center at University of Louisville
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

UofL Health Medical Center Northeast
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinicaltrials@sfmc-gi.org

Shepherdsville
Jewish Hospital Medical Center South
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinicaltrials@sfmc-gi.org

LA
Baton Rouge
LSU Health Baton Rouge-North Clinic
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinicalresearch@marybird.com

Louisiana Hematology Oncology Associates LLC
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinicalresearch@marybird.com

Mary Bird Perkins Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinicalresearch@marybird.com

Medical Center of Baton Rouge
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Camille.Beck@Ochsner.org

Ochsner Health Center-Summa
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Camille.Beck@Ochsner.org

Ochsner High Grove
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Gregory.Johnstone@ochsner.org

Our Lady of the Lake Physicians Group - Medical Oncology
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinicalresearch@marybird.com

Covington
Mary Bird Perkins Cancer Center - Covington
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinicalresearch@marybird.com

Northshore Oncology Associates-Covington
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinicalresearch@marybird.com

Houma
Mary Bird Perkins Cancer Center - Houma
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinicalresearch@marybird.com

Oncology Center of The South Incorporated
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinicalresearch@marybird.com

Kenner
Ochsner Medical Center Kenner
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: cris.molina@ochsner.org

Monroe
Ochsner LSU Health Monroe Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: LPost@lsuhsc.edu

New Orleans
Louisiana State University Health Science Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: emede1@lsuhsc.edu

Ochsner Medical Center Jefferson
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Gregory.Johnstone@ochsner.org

University Medical Center New Orleans
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: emede1@lsuhsc.edu

Shreveport
LSU Health Sciences Center at Shreveport
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: LPost@lsuhsc.edu

MA
Springfield
Baystate Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: tamara.wrenn@baystatehealth.org

Mercy Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Worcester
UMass Memorial Medical Center - University Campus
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: cancer.research@umassmed.edu

MD
Baltimore
Greater Baltimore Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

MedStar Franklin Square Medical Center / Weinberg Cancer Institute
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Saint Agnes Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Frederick
FMH James M Stockman Cancer Institute
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Frederick Memorial Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinicaltrials@fmh.org

MI
Adrian
Hickman Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Ann Arbor
Saint Joseph Mercy Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: stephanie.couch@stjoeshealth.org

University of Michigan Comprehensive Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Battle Creek
Bronson Battle Creek
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: crcwm-regulatory@crcwm.org

Brighton
Saint Joseph Mercy Brighton
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: stephanie.couch@stjoeshealth.org

Trinity Health IHA Medical Group Hematology Oncology - Brighton
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: stephanie.couch@stjoeshealth.org

Canton
Saint Joseph Mercy Canton
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: stephanie.couch@stjoeshealth.org

Trinity Health IHA Medical Group Hematology Oncology - Canton
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: stephanie.couch@stjoeshealth.org

Caro
Caro Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: stephanie.couch@stjoeshealth.org

Chelsea
Saint Joseph Mercy Chelsea
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: stephanie.couch@stjoeshealth.org

Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: stephanie.couch@stjoeshealth.org

Clarkston
Hematology Oncology Consultants-Clarkston
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: stephanie.couch@stjoeshealth.org

Newland Medical Associates-Clarkston
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: stephanie.couch@stjoeshealth.org

Dearborn
Beaumont Hospital - Dearborn
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Detroit
Ascension Saint John Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: stephanie.couch@stjoeshealth.org

Wayne State University / Karmanos Cancer Institute
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: ctoadmin@karmanos.org

East China
Great Lakes Cancer Management Specialists-Doctors Park
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: stephanie.couch@stjoeshealth.org

Escanaba
Green Bay Oncology - Escanaba
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: ewd_research_admin@hshs.org

Farmington Hills
Weisberg Cancer Treatment Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: ctoadmin@karmanos.org

Flint
Genesee Cancer and Blood Disease Treatment Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: stephanie.couch@stjoeshealth.org

Genesee Hematology Oncology PC
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: stephanie.couch@stjoeshealth.org

Genesys Hurley Cancer Institute
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: stephanie.couch@stjoeshealth.org

Hurley Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: stephanie.couch@stjoeshealth.org

Grand Rapids
Mercy Health Saint Mary's
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: crcwm-regulatory@crcwm.org

Spectrum Health at Butterworth Campus
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: crcwm-regulatory@crcwm.org

Grosse Pointe Woods
Academic Hematology Oncology Specialists
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: stephanie.couch@stjoeshealth.org

Great Lakes Cancer Management Specialists-Van Elslander Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: stephanie.couch@stjoeshealth.org

Michigan Breast Specialists-Grosse Pointe Woods
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: stephanie.couch@stjoeshealth.org

Jackson
Allegiance Health
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: CTOResearch@hfhs.org

Kalamazoo
Borgess Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: crcwm-regulatory@crcwm.org

Bronson Methodist Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: crcwm-regulatory@crcwm.org

West Michigan Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: crcwm-regulatory@crcwm.org

Lansing
Sparrow Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: stephanie.couch@stjoeshealth.org

Livonia
Hope Cancer Clinic
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: stephanie.couch@stjoeshealth.org

Trinity Health Saint Mary Mercy Livonia Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: stephanie.couch@stjoeshealth.org

Macomb Township
Great Lakes Cancer Management Specialists-Macomb Medical Campus
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: stephanie.couch@stjoeshealth.org

Michigan Breast Specialists-Macomb Township
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: stephanie.couch@stjoeshealth.org

Marlette
Saint Mary's Oncology / Hematology Associates of Marlette
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: stephanie.couch@stjoeshealth.org

Monroe
Toledo Clinic Cancer Centers-Monroe
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Muskegon
Mercy Health Mercy Campus
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: crcwm-regulatory@crcwm.org

Norton Shores
Cancer and Hematology Centers of Western Michigan - Norton Shores
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: connie.szczepanek@crcwm.org

Pontiac
21st Century Oncology-Pontiac
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: stephanie.couch@stjoeshealth.org

Hope Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: stephanie.couch@stjoeshealth.org

Newland Medical Associates-Pontiac
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: stephanie.couch@stjoeshealth.org

Saint Joseph Mercy Oakland
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: stephanie.couch@stjoeshealth.org

Port Huron
Huron Medical Center PC
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@sncrf.org

Lake Huron Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@sncrf.org

Reed City
Spectrum Health Reed City Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: crcwm-regulatory@crcwm.org

Rochester Hills
Great Lakes Cancer Management Specialists-Rochester Hills
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: stephanie.couch@stjoeshealth.org

Saginaw
Ascension Saint Mary's Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: stephanie.couch@stjoeshealth.org

Oncology Hematology Associates of Saginaw Valley PC
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: stephanie.couch@stjoeshealth.org

Sterling Heights
Bhadresh Nayak MD PC-Sterling Heights
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: stephanie.couch@stjoeshealth.org

Tawas City
Ascension Saint Joseph Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: stephanie.couch@stjoeshealth.org

Traverse City
Munson Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: crcwm-regulatory@crcwm.org

Warren
Advanced Breast Care Center PLLC
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: stephanie.couch@stjoeshealth.org

Great Lakes Cancer Management Specialists-Macomb Professional Building
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: stephanie.couch@stjoeshealth.org

Macomb Hematology Oncology PC
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: stephanie.couch@stjoeshealth.org

Michigan Breast Specialists-Warren
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: stephanie.couch@stjoeshealth.org

Saint John Macomb-Oakland Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: stephanie.couch@stjoeshealth.org

West Branch
Saint Mary's Oncology / Hematology Associates of West Branch
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: stephanie.couch@stjoeshealth.org

Wyoming
Metro Health Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: crcwm-regulatory@crcwm.org

Ypsilanti
Huron Gastroenterology PC
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: stephanie.couch@stjoeshealth.org

Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: stephanie.couch@stjoeshealth.org

MN
Aitkin
Riverwood Healthcare Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: CancerTrials@EssentiaHealth.org

Bemidji
Sanford Joe Lueken Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: OncologyClinicalTrialsFargo@sanfordhealth.org

Brainerd
Essentia Health Saint Joseph's Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: CancerTrials@EssentiaHealth.org

Coon Rapids
Mercy Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: mmcorc@healthpartners.com

Deer River
Essentia Health - Deer River Clinic
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: CancerTrials@EssentiaHealth.org

Detroit Lakes
Essentia Health Saint Mary's - Detroit Lakes Clinic
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: CancerTrials@EssentiaHealth.org

Duluth
Essentia Health Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: CancerTrials@EssentiaHealth.org

Essentia Health Saint Mary's Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: CancerTrials@EssentiaHealth.org

Miller-Dwan Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: CancerTrials@EssentiaHealth.org

Edina
Fairview Southdale Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: mmcorc@healthpartners.com

Fergus Falls
Lake Region Healthcare Corporation-Cancer Care
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: CancerTrials@EssentiaHealth.org

Fosston
Essentia Health - Fosston
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: CancerTrials@EssentiaHealth.org

Fridley
Unity Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: mmcorc@healthpartners.com

Hibbing
Essentia Health Hibbing Clinic
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Maplewood
Minnesota Oncology Hematology PA-Maplewood
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: mmcorc@healthpartners.com

Minneapolis
Abbott-Northwestern Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: mmcorc@healthpartners.com

Health Partners Inc
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: mmcorc@healthpartners.com

Hennepin County Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: mmcorc@healthpartners.com

Park Rapids
Essentia Health - Park Rapids
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: CancerTrials@EssentiaHealth.org

Robbinsdale
North Memorial Medical Health Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: mmcorc@healthpartners.com

Saint Paul
Regions Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: mmcorc@healthpartners.com

United Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: mmcorc@healthpartners.com

Sandstone
Essentia Health Sandstone
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: CancerTrials@EssentiaHealth.org

Shakopee
Saint Francis Regional Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: mmcorc@healthpartners.com

Stillwater
Lakeview Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: mmcorc@healthpartners.com

Thief River Falls
Sanford Thief River Falls Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Virginia
Essentia Health Virginia Clinic
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: CancerTrials@EssentiaHealth.org

Waconia
Ridgeview Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: mmcorc@healthpartners.com

Woodbury
Minnesota Oncology Hematology PA-Woodbury
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: mmcorc@healthpartners.com

Worthington
Sanford Cancer Center Worthington
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

MO
Bolivar
Central Care Cancer Center - Bolivar
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: aroland@kccop.org

Bonne Terre
Parkland Health Center-Bonne Terre
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Cape Girardeau
Saint Francis Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: sfmc@sfmc.net

Southeast Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Farmington
Parkland Health Center - Farmington
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Jefferson City
Capital Region Southwest Campus
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: swooden@mail.crmc.org

Kansas City
Kansas City Veterans Affairs Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Research Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: aroland@kccop.org

The University of Kansas Cancer Center-South
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: ctnursenav@kumc.edu

Truman Medical Centers
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

University of Kansas Cancer Center - North
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: KUCC_Navigation@kumc.edu

Lee's Summit
University of Kansas Cancer Center - Lee's Summit
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: KUCC_Navigation@kumc.edu

Saint Joseph
Heartland Regional Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: linda.schumacher@mymlc.com

Saint Louis
Missouri Baptist Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Sainte Genevieve
Sainte Genevieve County Memorial Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Springfield
CoxHealth South Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Mercy Hospital Springfield
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Sullivan
Missouri Baptist Sullivan Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Sunset Hills
Missouri Baptist Outpatient Center-Sunset Hills
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

MS
Jackson
University of Mississippi Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Pascagoula
Singing River Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

MT
Anaconda
Community Hospital of Anaconda
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: mccinfo@mtcancer.org

Billings
Saint Vincent Frontier Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Bozeman
Bozeman Deaconess Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: mccinfo@mtcancer.org

Butte
Saint James Community Hospital and Cancer Treatment Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Great Falls
Benefis Healthcare- Sletten Cancer Institute
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: mccinfo@mtcancer.org

Helena
Saint Peter's Community Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: mccinfo@mtcancer.org

Kalispell
Kalispell Regional Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: mccinfo@mtcancer.org

Missoula
Saint Patrick Hospital - Community Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: amy.hanneman@providence.org

NC
Asheville
AdventHealth Infusion Center Asheville
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: AMBER.WHEELER@AdventHealth.com

Clemmons
Wake Forest University at Clemmons
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Clinton
Southeastern Medical Oncology Center-Clinton
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: jfields@cancersmoc.com

Goldsboro
Southeastern Medical Oncology Center-Goldsboro
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: jfields@cancersmoc.com

Wayne Memorial Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: ecooke@cancersmoc.com

Hendersonville
Margaret R Pardee Memorial Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: karen.morris@unchealth.unc.edu

Jacksonville
Onslow Memorial Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: ecooke@cancersmoc.com

Southeastern Medical Oncology Center-Jacksonville
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: jfields@cancersmoc.com

Kenansville
Vidant Oncology-Kenansville
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Carla.Zimmerman@vidanthealth.com

Kinston
Vidant Oncology-Kinston
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Carla.Zimmerman@vidanthealth.com

Richlands
Vidant Oncology-Richlands
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Carla.Zimmerman@vidanthealth.com

Statesville
Wake Forest Baptist Health - Hematology Oncology - Statesville
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Wilkesboro
Wake Forest Baptist Health - Wilkes Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Winston-Salem
Wake Forest University Health Sciences
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

ND
Bismarck
Sanford Bismarck Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: OncologyClinicalTrialsFargo@sanfordhealth.org

Fargo
Essentia Health Cancer Center-South University Clinic
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: CancerTrials@EssentiaHealth.org

Sanford Broadway Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: OncologyClinicalTrialsFargo@sanfordhealth.org

Sanford Clinic North-Fargo
Status: ACTIVE
Contact: Preston D. Steen

Sanford Roger Maris Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: OncologyClinicalTrialsFargo@sanfordhealth.org

Sanford South University Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Jamestown
Essentia Health - Jamestown Clinic
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: CancerTrials@EssentiaHealth.org

NE
Bellevue
Nebraska Medicine-Bellevue
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: unmcrsa@unmc.edu

Grand Island
CHI Health Saint Francis
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Kearney
CHI Health Good Samaritan
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinicaltrials@sfmc-gi.org

Heartland Hematology and Oncology
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinicaltrials@sfmc-gi.org

Lincoln
Nebraska Cancer Research Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Nebraska Hematology and Oncology
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Saint Elizabeth Regional Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinicaltrials@sfmc-gi.org

Southeast Nebraska Cancer Center - 68th Street Place
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@cancerpartners.com

Norfolk
Faith Regional Health Services Carson Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: mwilwerding@canceralliance-ne.org

North Platte
Great Plains Health Callahan Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: mwilwerding@canceralliance-ne.org

Omaha
Alegent Health Bergan Mercy Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinicaltrials@sfmc-gi.org

Alegent Health Immanuel Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinicaltrials@sfmc-gi.org

Alegent Health Lakeside Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinicaltrials@sfmc-gi.org

Creighton University Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinicaltrials@sfmc-gi.org

Hematology and Oncology Consultants PC
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinicaltrials@sfmc-gi.org

Nebraska Cancer Specialists - Omaha
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: mwilwerding@canceralliance-ne.org

Nebraska Medicine-Village Pointe
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Nebraska Methodist Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Oncology Hematology West PC
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

University of Nebraska Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: unmcrsa@unmc.edu

Papillion
Midlands Community Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinicaltrials@sfmc-gi.org

Scottsbluff
Regional West Medical Center Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: mwilwerding@canceralliance-ne.org

NJ
Hackensack
Hackensack University Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

NM
Albuquerque
Lovelace Medical Center-Saint Joseph Square
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: AYost@nmcca.org

New Mexico Oncology Hematology Consultants
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: CLee@nmcca.org

Presbyterian Kaseman Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: WBurman@phs.org

University of New Mexico Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: LByatt@nmcca.org

Las Cruces
Memorial Medical Center - Las Cruces
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Kim.Hoffman@lpnt.net

Rio Rancho
Presbyterian Rust Medical Center / Jorgensen Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: WBurman@phs.org

NV
Carson City
Carson Tahoe Regional Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@sncrf.org

Henderson
Cancer and Blood Specialists-Henderson
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@sncrf.org

Comprehensive Cancer Centers of Nevada - Henderson
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@sncrf.org

Comprehensive Cancer Centers of Nevada-Horizon Ridge
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@sncrf.org

Comprehensive Cancer Centers of Nevada-Southeast Henderson
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@sncrf.org

GenesisCare USA - Henderson
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@sncrf.org

Las Vegas Cancer Center-Henderson
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@sncrf.org

Las Vegas Urology - Green Valley
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@sncrf.org

Las Vegas Urology - Pebble
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@sncrf.org

OptumCare Cancer Care at Seven Hills
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@sncrf.org

Urology Specialists of Nevada - Green Valley
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@sncrf.org

Las Vegas
Alliance for Childhood Diseases / Cure 4 the Kids Foundation
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@sncrf.org

Ann M Wierman MD LTD
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@sncrf.org

Cancer and Blood Specialists-Shadow
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@sncrf.org

Cancer and Blood Specialists-Tenaya
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@sncrf.org

Comprehensive Cancer Centers of Nevada
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@sncrf.org

Comprehensive Cancer Centers of Nevada - Central Valley
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@sncrf.org

Comprehensive Cancer Centers of Nevada - Northwest
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@sncrf.org

Comprehensive Cancer Centers of Nevada - Town Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@sncrf.org

Comprehensive Cancer Centers of Nevada-Summerlin
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@sncrf.org

Desert West Surgery
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@sncrf.org

GenesisCare USA - Fort Apache
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@sncrf.org

GenesisCare USA - Las Vegas
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@sncrf.org

GenesisCare USA - Vegas Tenaya
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@sncrf.org

HealthCare Partners Medical Group Oncology / Hematology-Centennial Hills
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@sncrf.org

HealthCare Partners Medical Group Oncology / Hematology-Maryland Parkway
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@sncrf.org

HealthCare Partners Medical Group Oncology / Hematology-San Martin
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@sncrf.org

HealthCare Partners Medical Group Oncology / Hematology-Tenaya
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@sncrf.org

Hope Cancer Care of Nevada
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@sncrf.org

Las Vegas Cancer Center-Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@sncrf.org

Las Vegas Prostate Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@sncrf.org

Las Vegas Urology - Cathedral Rock
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@sncrf.org

Las Vegas Urology - Pecos
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@sncrf.org

Las Vegas Urology - Smoke Ranch
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@smcrf.org

Las Vegas Urology - Sunset
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@sncrf.org

OptumCare Cancer Care at Charleston
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@sncrf.org

OptumCare Cancer Care at Fort Apache
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@sncrf.org

OptumCare Cancer Care at MountainView
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@sncrf.org

Radiation Oncology Centers of Nevada Central
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@sncrf.org

Radiation Oncology Centers of Nevada Southeast
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@sncrf.org

Summerlin Hospital Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@sncrf.org

Sunrise Hospital and Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@sncrf.org

University Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@sncrf.org

University Medical Center of Southern Nevada
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@sncrf.org

Urology Specialists of Nevada - Central
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@sncrf.org

Urology Specialists of Nevada - Northwest
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@sncrf.org

Urology Specialists of Nevada - Southwest
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@sncrf.org

Pahrump
Hope Cancer Care of Nevada-Pahrump
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@sncrf.org

Reno
Radiation Oncology Associates
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@sncrf.org

Renown Regional Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@sncrf.org

Saint Mary's Regional Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: research@sncrf.org

NY
Albany
New York Oncology Hematology PC - Albany Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: jennifer.moran@usoncology.com

Buffalo
Roswell Park Cancer Institute
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: askroswell@roswellpark.org

Cooperstown
Mary Imogene Bassett Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: CancerClinicalTrials@bassett.org

Rochester
University of Rochester
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Stony Brook
Stony Brook University Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Syracuse
State University of New York Upstate Medical University
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

OH
Beachwood
UHHS-Chagrin Highlands Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: CTUReferral@UHhospitals.org

Beavercreek
Indu and Raj Soin Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org

Belpre
Strecker Cancer Center-Belpre
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: sheree@columbusccop.org

Boardman
Saint Elizabeth Boardman Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org

Centerville
Dayton Physicians LLC-Miami Valley South
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org

Miami Valley Hospital South
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org

Chillicothe
Adena Regional Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: sheree@columbusccop.org

Cincinnati
Bethesda North Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinicaltrials@sfmc-gi.org

Good Samaritan Hospital - Cincinnati
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinicaltrials@sfmc-gi.org

Oncology Hematology Care Inc-Anderson
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org

Oncology Hematology Care Inc-Blue Ash
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org

Oncology Hematology Care Inc-Eden Park
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org

Oncology Hematology Care Inc-Kenwood
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org

Oncology Hematology Care Inc-Mercy West
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org

TriHealth Cancer Institute-Anderson
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinicaltrials@sfmc-gi.org

TriHealth Cancer Institute-Westside
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinicaltrials@sfmc-gi.org

University of Cincinnati Cancer Center-UC Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: cancer@uchealth.com

Cleveland
Case Western Reserve University
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: CTUReferral@UHhospitals.org

Cleveland Clinic Cancer Center / Fairview Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: TaussigResearch@ccf.org

Cleveland Clinic Foundation
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: TaussigResearch@ccf.org

MetroHealth Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: dstrater@metrohealth.org

Columbus
Columbus Oncology and Hematology Associates Inc
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: sheree@columbusccop.org

Doctors Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: sheree@columbusccop.org

Grant Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: sheree@columbusccop.org

Mount Carmel East Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: sheree@columbusccop.org

Mount Carmel Health Center West
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: sheree@columbusccop.org

Ohio State University Comprehensive Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Jamesline@osumc.edu

Riverside Methodist Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: sheree@columbusccop.org

The Mark H Zangmeister Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: sheree@columbusccop.org

Dayton
Dayton Physician LLC-Miami Valley Hospital North
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org

Good Samaritan Hospital - Dayton
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org

Miami Valley Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org

Miami Valley Hospital North
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org

Delaware
Delaware Health Center-Grady Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: sheree@columbusccop.org

Grady Memorial Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: sheree@columbusccop.org

Dublin
Dublin Methodist Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: sheree@columbusccop.org

Fairfield
Oncology Hematology Care Inc-Healthplex
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org

Findlay
Armes Family Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org

Blanchard Valley Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org

Orion Cancer Care
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org

Franklin
Atrium Medical Center-Middletown Regional Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org

Dayton Physicians LLC-Atrium
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org

Greenville
Dayton Physicians LLC-Wayne
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org

Wayne Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org

Grove City
Mount Carmel Grove City Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: sheree@columbusccop.org

Independence
Cleveland Clinic Cancer Center Independence
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: TaussigResearch@ccf.org

Kettering
Greater Dayton Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org

Kettering Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org

Lancaster
Fairfield Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: sheree@columbusccop.org

Lima
Saint Rita's Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Mansfield
Cleveland Clinic Cancer Center Mansfield
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: TaussigResearch@ccf.org

Marietta
Marietta Memorial Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: sheree@columbusccop.org

Marion
OhioHealth Marion General Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: sheree@columbusccop.org

Maumee
Toledo Clinic Cancer Centers-Maumee
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Toledo Radiation Oncology at Northwest Ohio Onocolgy Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Mayfield Heights
Hillcrest Hospital Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: TaussigResearch@ccf.org

Middletown
Dayton Physicians LLC-Signal Point
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org

Mount Vernon
Knox Community Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: sheree@columbusccop.org

Newark
Licking Memorial Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: sheree@columbusccop.org

Newark Radiation Oncology
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: sheree@columbusccop.org

Oregon
Saint Charles Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Perrysburg
Mercy Health Perrysburg Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: sheree@columbusccop.org

Portsmouth
Southern Ohio Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: sheree@columbusccop.org

Sandusky
North Coast Cancer Care
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: TaussigResearch@ccf.org

Sidney
Dayton Physicians LLC-Wilson
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org

Springfield
Springfield Regional Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org

Springfield Regional Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org

Strongsville
Cleveland Clinic Cancer Center Strongsville
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: TaussigResearch@ccf.org

Toledo
Mercy Health - Saint Anne Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: sheree@columbusccop.org

Saint Vincent Mercy Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: sheree@columbusccop.org

Toledo Clinic Cancer Centers-Toledo
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

University of Toledo
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Troy
Dayton Physicians LLC-Upper Valley
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org

Upper Valley Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org

Warren
Saint Joseph Warren Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org

Warrensville Heights
South Pointe Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: TaussigResearch@ccf.org

West Chester
University of Cincinnati Cancer Center-West Chester
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: cancer@uchealth.com

Westerville
Saint Ann's Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: sheree@columbusccop.org

Westlake
UHHS-Westlake Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: CTUReferral@UHhospitals.org

Wooster
Cleveland Clinic Wooster Family Health and Surgery Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: TaussigResearch@ccf.org

Youngstown
Saint Elizabeth Youngstown Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org

Zanesville
Genesis Healthcare System Cancer Care Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: sheree@columbusccop.org

OK
Oklahoma City
Integris Southwest Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: ctsucontact@westat.com

University of Oklahoma Health Sciences Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: ou-clinical-trials@ouhsc.edu

OR
Baker City
Saint Alphonsus Medical Center-Baker City
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: mccinfo@mtcancer.org

Bend
Saint Charles Health System
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: nosall@stcharleshealthcare.org

Clackamas
Clackamas Radiation Oncology Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: CanRsrchStudies@providence.org

Providence Cancer Institute Clackamas Clinic
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: CanRsrchStudies@providence.org

Coos Bay
Bay Area Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: cherie.cox@bayareahospital.org

Newberg
Providence Newberg Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: CanRsrchStudies@providence.org

Ontario
Saint Alphonsus Medical Center-Ontario
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: mccinfo@mtcancer.org

Oregon City
Providence Willamette Falls Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: CanRsrchStudies@providence.org

Portland
Oregon Health and Science University
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: trials@ohsu.edu

Providence Portland Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: CanRsrchStudies@providence.org

Providence Saint Vincent Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: CanRsrchStudies@providence.org

Redmond
Saint Charles Health System-Redmond
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

PA
Allentown
Lehigh Valley Hospital-Cedar Crest
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: stephanie.couch@stjoeshealth.org

Beaver
UPMC-Heritage Valley Health System Beaver
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: haneydl@upmc.edu

Bethlehem
Lehigh Valley Hospital - Muhlenberg
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: stephanie.couch@stjoeshealth.org

Saint Luke's University Hospital-Bethlehem Campus
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Chadds Ford
Christiana Care Health System-Concord Health Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: mhayden@christianacare.org

Chambersburg
Chambersburg Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: ctsucontact@westat.com

Danville
Geisinger Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: HemonCCTrials@geisinger.edu

East Stroudsburg
Pocono Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: stephanie.couch@stjoeshealth.org

Ephrata
Ephrata Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Ephrata Community Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: ctsucontact@westat.com

Gettysburg
Adams Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Greensburg
UPMC Cancer Centers - Arnold Palmer Pavilion
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Hanover
Cherry Tree Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Hazleton
Geisinger Medical Center-Cancer Center Hazleton
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: HemonCCTrials@geisinger.edu

Lehigh Valley Hospital-Hazleton
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: stephanie.couch@stjoeshealth.org

Hershey
Penn State Milton S Hershey Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: CTO@hmc.psu.edu

Johnstown
UPMC-Johnstown / John P. Murtha Regional Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Lebanon
Sechler Family Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: doxenberg@wellspan.org

Lewisburg
Geisinger Medical Oncology-Lewisburg
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: HemonCCTrials@geisinger.edu

Lewistown
Lewistown Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: HemonCCTrials@geisinger.edu

McKeesport
UPMC Cancer Center at UPMC McKeesport
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Moon Township
UPMC-Coraopolis / Heritage Valley Radiation Oncology
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Pittsburgh
Allegheny General Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

UPMC-Magee Womens Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

UPMC-Passavant Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

UPMC-Presbyterian Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

UPMC-Saint Clair Hospital Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

UPMC-Saint Margaret
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

UPMC-Shadyside Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

University of Pittsburgh Cancer Institute (UPCI)
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

West Penn Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Pottsville
Geisinger Cancer Services-Pottsville
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: HemonCCTrials@geisinger.edu

Sayre
Guthrie Medical Group PC-Robert Packer Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Scranton
Community Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: HemonCCTrials@geisinger.edu

Selinsgrove
Geisinger Medical Oncology-Selinsgrove
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: HemonCCTrials@geisinger.edu

Seneca
UPMC Cancer Center at UPMC Northwest
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

State College
Geisinger Medical Group
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: HemonCCTrials@geisinger.edu

Uniontown
UPMC Uniontown Hospital Radiation Oncology
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Washington
UPMC Washington Hospital Radiation Oncology
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: cancer@washingtonhospital.org

West Reading
Reading Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Wexford
Wexford Health and Wellness Pavilion
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: ddefazio@wpahs.org

Wilkes-Barre
Geisinger Wyoming Valley / Henry Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: HemonCCTrials@geisinger.edu

York
WellSpan Health-York Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

WellSpan Health-York Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

RI
Providence
Rhode Island Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

SC
Anderson
AnMed Health Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: rhonda.ballew@anmedhealth.org

Bluffton
Saint Joseph's / Candler - Bluffton Campus
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: underberga@sjchs.org

Boiling Springs
Prisma Health Cancer Institute - Spartanburg
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: kim.williams3@prismahealth.org

Charleston
Charleston Oncology - Roper
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Heather.Dubose@choasc.com

Charleston Oncology - Saint Francis
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Heather.Dubose@choasc.com

Medical University of South Carolina
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: hcc-clinical-trials@musc.edu

Roper Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Courtney.Roldan@RoperSaintFrancis.com

Easley
Prisma Health Cancer Institute - Easley
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: kim.williams3@prismahealth.org

Greenville
Prisma Health Cancer Institute - Butternut
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: kim.williams3@prismahealth.org

Prisma Health Cancer Institute - Eastside
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: kim.williams3@prismahealth.org

Prisma Health Cancer Institute - Faris
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: kim.williams3@prismahealth.org

Prisma Health Greenville Memorial Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: kim.williams3@prismahealth.org

Saint Francis Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: melissa_beckman@bshsi.org

Saint Francis Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: melissa_beckman@bshsi.org

Greer
Prisma Health Cancer Institute - Greer
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: kim.williams3@prismahealth.org

Hilton Head Island
South Carolina Cancer Specialists PC
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: underberga@sjchs.org

The Radiation Oncology Center-Hilton Head / Bluffton
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: underberga@sjchs.org

Seneca
Prisma Health Cancer Institute - Seneca
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: kim.williams3@prismahealth.org

SD
Sioux Falls
Avera Cancer Institute
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: OncRegulatory@avera.org

Sanford Cancer Center Oncology Clinic
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: OncologyClinicTrialsSF@sanfordhealth.org

Sanford USD Medical Center - Sioux Falls
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: OncologyClinicalTrialsSF@SanfordHealth.org

TN
Bristol
Bristol Regional Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: justin.reynolds@wellmont.org

Wellmont Medical Associates Oncology and Hematology-Bristol
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Chattanooga
Erlanger Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Memorial Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinicaltrials@sfmc-gi.org

Franklin
Vanderbilt-Ingram Cancer Center Cool Springs
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Hixson
Pulmonary Medicine Center of Chattanooga-Hixson
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinicaltrials@sfmc-gi.org

Kingsport
Ballad Health Cancer Care – Kingsport
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Justin.reynolds@balladhealth.org

Wellmont Holston Valley Hospital and Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: justin.reynolds@wellmont.org

Knoxville
Thompson Cancer Survival Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Thompson Cancer Survival Center - West
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Maryville
Thompson Oncology Group-Maryville
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Nashville
Vanderbilt Breast Center at One Hundred Oaks
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Vanderbilt University / Ingram Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Oak Ridge
Thompson Oncology Group-Oak Ridge
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Ooltewah
Memorial GYN Plus
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinicaltrials@sfmc-gi.org

TX
Bryan
Saint Joseph Regional Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: clinicaltrials@sfmc-gi.org

Dallas
Parkland Memorial Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: canceranswerline@UTSouthwestern.edu

UT Southwestern / Simmons Cancer Center-Dallas
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: canceranswerline@UTSouthwestern.edu

UT
American Fork
American Fork Hospital / Huntsman Intermountain Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: officeofresearch@imail.org

Cedar City
Sandra L Maxwell Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: officeofresearch@imail.org

Logan
Logan Regional Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: officeofresearch@imail.org

Murray
Intermountain Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: officeofresearch@imail.org

Ogden
McKay-Dee Hospital Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: officeofresearch@imail.org

Provo
Utah Valley Regional Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: officeofresearch@imail.org

Riverton
Riverton Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: officeofresearch@imail.org

Saint George
Saint George Regional Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: officeofresearch@imail.org

Salt Lake City
Huntsman Cancer Institute / University of Utah
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: cancerinfo@hci.utah.edu

LDS Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: officeofresearch@imail.org

Utah Cancer Specialists-Salt Lake City
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: officeofresearch@imail.org

VA
Bristol
Wellmont Medical Associates-Bristol
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: justin.reynolds@wellmont.org

Charlottesville
University of Virginia Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: uvacancertrials@hscmail.mcc.virginia.edu

Lynchburg
Centra Lynchburg Hematology-Oncology Clinic Inc
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Kevin.Patel@centrahealth.com

Norton
Southwest VA Regional Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: justin.reynolds@wellmont.org

Richmond
Virginia Commonwealth University / Massey Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: CTOclinops@vcu.edu

WI
Antigo
Langlade Hospital and Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Juli.Alford@aspirus.org

Ashland
Duluth Clinic Ashland
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: CancerTrials@EssentiaHealth.org

Northwest Wisconsin Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: CancerTrials@EssentiaHealth.org

Chippewa Falls
Marshfield Clinic-Chippewa Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: oncology.clinical.trials@marshfieldresearch.org

Eau Claire
Marshfield Clinic Cancer Center at Sacred Heart
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: oncology.clinical.trials@marshfieldresearch.org

Marshfield Medical Center-EC Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: oncology.clinical.trials@marshfieldresearch.org

Green Bay
Bellin Memorial Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Green Bay Oncology Limited at Saint Mary's Hospital
Status: ACTIVE
Contact: Brian Leslie Burnette

Green Bay Oncology at Saint Vincent Hospital
Status: ACTIVE
Contact: Brian Leslie Burnette

Saint Vincent Hospital Cancer Center Green Bay
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: ewd_research_admin@hshs.org

Saint Vincent Hospital Cancer Center at Saint Mary's
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: ewd_research_admin@hshs.org

Johnson Creek
UW Cancer Center Johnson Creek
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: lynda.persico@uwmf.wisc.edu

La Crosse
Gundersen Lutheran Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: cancerctr@gundersenhealth.org

Ladysmith
Marshfield Clinic - Ladysmith Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: oncology.clinical.trials@marshfieldresearch.org

Madison
University of Wisconsin Carbone Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Manitowoc
Holy Family Memorial Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Marinette
Saint Vincent Hospital Cancer Center at Marinette
Status: TEMPORARILY_CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Christy.Gilchrist@hshs.org

Marshfield
Marshfield Medical Center-Marshfield
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: oncology.clinical.trials@marshfieldresearch.org

Medford
Aspirus Medford Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: Beth.Knetter@aspirus.org

Milwaukee
Ascension Southeast Wisconsin Hospital - Saint Joseph Campus
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: AWRI.Inquiry@Ascension.org

Medical College of Wisconsin
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Minocqua
Marshfield Clinic-Minocqua Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: oncology.clinical.trials@marshfieldresearch.org

New Richmond
Cancer Center of Western Wisconsin
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: mmcorc@healthpartners.com

Oconto Falls
Saint Vincent Hospital Cancer Center at Oconto Falls
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: ewd_research_admin@hshs.org

Rice Lake
Lakeview Medical Center-Marshfield Clinic
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: oncology.clinical.trials@marshfieldresearch.org

Marshfield Medical Center-Rice Lake
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: oncology.clinical.trials@marshfieldresearch.org

Sheboygan
HSHS Saint Nicholas Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: ewd_research_admin@hshs.org

Stevens Point
Marshfield Medical Center-River Region at Stevens Point
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: oncology.clinical.trials@marshfieldresearch.org

Sturgeon Bay
Green Bay Oncology - Sturgeon Bay
Status: ACTIVE
Contact: Brian Leslie Burnette

Saint Vincent Hospital Cancer Center at Sturgeon Bay
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: ewd_research_admin@hshs.org

Wausau
Aspirus Regional Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Marshfield Clinic-Wausau Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: oncology.clinical.trials@marshfieldresearch.org

Weston
Marshfield Medical Center - Weston
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: oncology.clinical.trials@marshfieldresearch.org

Wisconsin Rapids
Aspirus Cancer Care - Wisconsin Rapids
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Marshfield Clinic - Wisconsin Rapids Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: oncology.clinical.trials@marshfieldresearch.org

WV
Bridgeport
United Hospital Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: cancertrialsinfo@hsc.wvu.edu

Charleston
West Virginia University Charleston Division
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Huntington
Edwards Comprehensive Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact

Martinsburg
WVUH-Berkely Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: cancertrialsinfo@hsc.wvu.edu

Morgantown
West Virginia University Healthcare
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: cancertrialsinfo@hsc.wvu.edu

Parkersburg
Camden Clark Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: Site Public Contact
Email: cancertrialsinfo@hsc.wvu.edu

PRIMARY OBJECTIVE:
I. To determine whether initial treatment with either combination ipilimumab + nivolumab (with subsequent dabrafenib mesylate [dabrafenib] in combination with trametinib dimethyl sulfoxide [trametinib]) or dabrafenib in combination with trametinib (with subsequent ipilimumab + nivolumab) significantly improves 2 year overall survival (OS) in patients with unresectable stage III or stage IV BRAFV600 mutant melanoma.

SECONDARY CLINICAL OBJECTIVES:
I. To evaluate the impact of initial treatment on median OS and hazard ratio for death.
II. To determine whether initial treatment choice significantly improves 3 year OS.
III. To evaluate the anti-tumor activities (Response Evaluation Criteria in Solid Tumors [RECIST]-defined response rate, median progression-free survival [PFS]) and safety profiles of ipilimumab + nivolumab and dabrafenib-trametinib in a Cooperative Group trial of patients with V600 mutant melanoma.
IV. To evaluate the activity (RECIST-defined response rate, median PFS) and safety of dabrafenib + trametinib in patients who have had disease progression on ipilimumab + nivolumab and in comparison to its activity and safety in ipilimumab + nivolumab naive patients.
V. To evaluate the activity of ipilimumab + nivolumab (RECIST-defined response rate, median PFS) and safety in patients who have had disease progression on dabrafenib + trametinib and in comparison to its activity and safety in dabrafenib + trametinib naive patients.
VI. To assess the feasibility of crossover to the alternative treatment strategy (percentage of patients who are able to crossover from one arm to the other and complete at least an initial course [12 weeks] of treatment after cross-over without intervening symptomatic disease progression or treatment limiting toxicity).

SECONDARY LABORATORY OBJECTIVES:
I. Association of inherited variation with immune mediated adverse events and response to ipilimumab + nivolumab.
Ia. To determine the association of inherited genetic variation and immune-associated adverse events in patients with metastatic melanoma treated with ipilimumab containing regimens by completing candidate-based gene and pathway analyses of genes involved in lymphocyte activation, cytokines, cytokine receptors and within the major histocompatibility complex (MHC) region and an agnostic genome-wide single nucleotide polymorphism (SNP)-based approach;
Ib. To investigate the association between inherited genetics and survival in patients with metastatic melanoma treated with ipilimumab containing regimens by completing candidate-based gene and pathway analyses of genes involved in lymphocyte activation, cytokines profile, cytokine receptors and within the MHC region and an agnostic genome-wide SNP-based approach;
Ic. To replicate genomic markers identified in the above aims in an independent sample set of patients treated with ipilimumab containing regimens and preliminarily characterize their potential functional role by completing replication of variation as associated with immune-related adverse events (irAEs) and survival and bio-informatic assessment of genomic markers.
II. To determine the utility of circulating BRAF levels in determining the response and resistance to either BRAF/MEK directed and/or combination immunotherapy in patients with BRAF mutant melanoma.
IIa. To determine if changes in blood BRAF levels utilizing peripheral blood BRAFV600 mutational testing in patients with stage IV BRAF mutant melanoma correlate with response and resistance to combination BRAF/MEK directed therapy;
IIb. To determine if changes in blood BRAF levels utilizing peripheral blood BRAFV600 mutational testing in patients with stage IV BRAF mutant melanoma correlate with response and resistance to combination immunotherapy;
IIc. To compare the kinetics of peripheral blood BRAFV600 levels during response and resistance in groups of patients receiving BRAF targeted therapy or combination immunotherapy as initial therapy;
IId. To compare the kinetics of peripheral blood BRAFV600 levels during response and resistance to combination BRAF targeted therapy or combination immunotherapy in individual patients (initial treatment versus [vs] crossover treatment).

SECONDARY PATIENT REPORTED OUTCOMES OBJECTIVES:
I. To evaluate differences in overall health between initial treatment arms (dabrafenib + trametinib vs. ipilimumab + nivolumab immunotherapy) at 2 years, accounting for toxicities and overall survival. (Primary)
II. To assess differences in overall function over 2 years between initial treatment with dabrafenib + trametinib vs. ipilimumab + nivolumab. (Secondary)
III. To document the effects of treatment crossover and treatment administration sequence on symptom burden and overall function. (Secondary)
IIIa. To compare differences in function and symptoms by treatment sequence for ipilimumab + nivolumab (arm A vs. D), and dabrafenib + trametinib, (arm B vs. C) at baseline, 6 weeks, 12 weeks, and 6 months after the initiation of each treatment;
IIIb. To describe the frequency and severity of treatment toxicities at baseline, 6 weeks, 12 weeks, and 6 months after initiation of each treatment.

EXPLORATORY TOBACCO USE OBJECTIVES:
I. To determine the effects of tobacco, operationalized as combustible tobacco (1a), other forms of tobacco (1b), and environmental tobacco exposure (ETS) (1c) on provider-reported cancer-treatment toxicity (adverse events [both clinical and hematologic] and dose modifications).
II. To determine the effects of tobacco on patient-reported physical symptoms and psychological symptoms.
III. To examine quitting behaviors and behavioral counseling/support and cessation medication utilization.
IV. To explore the effect of tobacco use and exposure on treatment duration, relative dose intensity, and therapeutic benefit.

EXPLORATORY CORRELATIVE OBJECTIVES:
I. To assess serum based biomarkers of efficacy and adverse events due to treatment with immune checkpoint inhibitors.
II. To monitor tumor response by comparing changes in circulating cell-free mutant tumor deoxyribonucleic acid (DNA) (ctDNA) as a readout of tumor burden (a) at week 12 relative to baseline before treatment in responders and non-responders; (b) before and during immunosuppressive treatment to control irAEs.
III. To monitor organ-specific adverse events (irAEs) using circulating cell-free, tissue-specific methylated DNA (cmeDNA) as a readout of tissue-specific toxicity (a) at the time of grade 3-4 irAE relative to baseline and control patients without irAEs; (b) during immunosuppressive treatment for irAEs.

OUTLINE: Patients are randomized to 1 of 2 treatment arms (Arm A or Arm B).

ARM A:
IMMUNOTHERAPY INDUCTION (CYCLES 1-2): Patients receive nivolumab intravenously (IV) over 30-60 minutes and ipilimumab IV over 30-90 minutes on days 1 and 22. Treatment repeats every 6 weeks for 2 cycles in the absence of disease progression or unacceptable toxicity.

IMMUNOTHERAPY MAINTENANCE (CYCLES 3-14): Patients receive nivolumab IV over 30-60 minutes on days 1, 15, and 29. Treatment repeats every 6 weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Upon disease progression (or before), patients re-register and cross over to Arm C. 
Patients undergo computed tomography (CT) at baseline, and day 1 of cycles 3-14. Patients undergo echocardiogram (ECHO) or multigated acquisition scan (MUGA) at baseline and end of treatment. 

ARM C: Patients receive dabrafenib mesylate orally (PO) twice daily (BID) and trametinib dimethyl sulfoxide PO daily on days 1-42. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
Patients undergo CT at baseline, and day 1 of each cycle. Patients undergo ECHO or MUGA day 1 of each cycle and end of treatment. 

ARM B: Patients receive dabrafenib mesylate PO BID and trametinib dimethyl sulfoxide PO daily on days 1-42. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Upon disease progression (or before), patients re-register and cross over to Arm D.
Patients undergo CT at baseline, and day 1 of each cycle. Patients undergo ECHO or MUGA day 1 of each cycle and end of treatment. 

ARM D:
IMMUNOTHERAPY INDUCTION (CYCLES 1-2): Patients receive nivolumab IV over 30-60 minutes and ipilimumab IV over 30-90 minutes on days 1 and 22. Treatment repeats every 6 weeks for 2 cycles in the absence of disease progression or unacceptable toxicity.
Patients undergo CT at baseline, and day 1 of each cycle. Patients undergo ECHO or MUGA day 1 of each cycle and end of treatment. 
IMMUNOTHERAPY MAINTENANCE (CYCLES 3-14): Patients receive nivolumab IV over 30-60 minutes on days 1, 15, and 29. Treatment repeats every 6 weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
Patients undergo CT at baseline, and day 1 of cycles 3-14. Patients undergo ECHO or MUGA at end of treatment.  

After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 3 years.

Interactive content above is from the official study record on the National Cancer Institute website, cancer.gov.


The ECOG-ACRIN Cancer Research Group designed and conducted this trial with funding from the National Cancer Institute through its National Clinical Trials Network.


EA6134 / DREAMseq (Closed)
ECOG-ACRIN Cancer Research Group